These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
927 related articles for article (PubMed ID: 23746142)
1. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α. Tsimafeyeu I; Zart JS; Chung B BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142 [TBL] [Abstract][Full Text] [Related]
2. Commentary on "Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α." Tsimafeyeu I, Zart JS, Chung B, Kidney Cancer Research Bureau, Moscow, Russian Federation.: BJU Int 2013; 112(1):32-8. [Epub 2013 Jun 7]. doi: 10.1111/bju.12107. Boorjian S Urol Oncol; 2014 May; 32(4):514-5. PubMed ID: 24767689 [TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib. Yuasa T; Tsuchiya N; Urakami S; Horikawa Y; Narita S; Inoue T; Saito M; Yamamoto S; Yonese J; Fukui I; Nakano K; Takahashi S; Hatake K; Habuchi T BJU Int; 2012 May; 109(9):1349-54. PubMed ID: 21883864 [TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib. Beuselinck B; Vano YA; Oudard S; Wolter P; De Smet R; Depoorter L; Teghom C; Karadimou A; Zucman-Rossi J; Debruyne PR; Van Poppel H; Joniau S; Lerut E; Strijbos M; Dumez H; Paridaens R; Van Calster B; Schöffski P BJU Int; 2014 Jul; 114(1):81-9. PubMed ID: 24215209 [TBL] [Abstract][Full Text] [Related]
5. Sunitinib in metastatic renal cell carcinoma: Experience from single center study, efficacy and safety. Patel KB; Panchal HP; Karanwal AB; Parekh BB; Shah S; Prasad S Indian J Cancer; 2016; 53(1):118-22. PubMed ID: 27146758 [TBL] [Abstract][Full Text] [Related]
6. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860 [TBL] [Abstract][Full Text] [Related]
7. Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib. Terakawa T; Miyake H; Kusuda Y; Fujisawa M Urol Oncol; 2013 May; 31(4):493-8. PubMed ID: 21478036 [TBL] [Abstract][Full Text] [Related]
8. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Heng DY; Chi KN; Murray N; Jin T; Garcia JA; Bukowski RM; Rini BI; Kollmannsberger C Cancer; 2009 Feb; 115(4):776-83. PubMed ID: 19127560 [TBL] [Abstract][Full Text] [Related]
9. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib. Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030 [TBL] [Abstract][Full Text] [Related]
11. Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry. de Groot S; Redekop WK; Sleijfer S; Oosterwijk E; Bex A; Kiemeney LA; Uyl-de Groot CA Urology; 2016 Sep; 95():121-7. PubMed ID: 27179773 [TBL] [Abstract][Full Text] [Related]
13. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Uemura H; Shinohara N; Yuasa T; Tomita Y; Fujimoto H; Niwakawa M; Mugiya S; Miki T; Nonomura N; Takahashi M; Hasegawa Y; Agata N; Houk B; Naito S; Akaza H Jpn J Clin Oncol; 2010 Mar; 40(3):194-202. PubMed ID: 19897852 [TBL] [Abstract][Full Text] [Related]
14. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. Porta C; Procopio G; Cartenì G; Sabbatini R; Bearz A; Chiappino I; Ruggeri EM; Re GL; Ricotta R; Zustovich F; Landi L; Calcagno A; Imarisio I; Verzoni E; Rizzo M; Paglino C; Guadalupi V; Bajetta E BJU Int; 2011 Oct; 108(8 Pt 2):E250-7. PubMed ID: 21599821 [TBL] [Abstract][Full Text] [Related]
15. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. Méjean A; Ravaud A; Thezenas S; Colas S; Beauval JB; Bensalah K; Geoffrois L; Thiery-Vuillemin A; Cormier L; Lang H; Guy L; Gravis G; Rolland F; Linassier C; Lechevallier E; Beisland C; Aitchison M; Oudard S; Patard JJ; Theodore C; Chevreau C; Laguerre B; Hubert J; Gross-Goupil M; Bernhard JC; Albiges L; Timsit MO; Lebret T; Escudier B N Engl J Med; 2018 Aug; 379(5):417-427. PubMed ID: 29860937 [TBL] [Abstract][Full Text] [Related]
16. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Négrier S; Gravis G; Pérol D; Chevreau C; Delva R; Bay JO; Blanc E; Ferlay C; Geoffrois L; Rolland F; Legouffe E; Sevin E; Laguerre B; Escudier B Lancet Oncol; 2011 Jul; 12(7):673-80. PubMed ID: 21664867 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis. Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858 [TBL] [Abstract][Full Text] [Related]
18. Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha. Dirican A; Kucukzeybek Y; Erten C; Somali I; Demir L; Can A; Payzin KB; Bayoglu IV; Akyol M; Yildiz Y; Koeseoglu M; Alacacioglu A; Tarhan MO Asian Pac J Cancer Prev; 2013; 14(3):2101-5. PubMed ID: 23679326 [TBL] [Abstract][Full Text] [Related]
19. Is Late Recurrence a Predictive Clinical Marker for Better Sunitinib Response in Metastatic Renal Cell Carcinoma Patients? Bozkurt O; Hacıbekiroglu I; Kaplan MA; Duzkopru Y; Uysal M; Karaca H; Berk V; Inanc M; Duran AO; Ozaslan E; Ucar M; Ozkan M Clin Genitourin Cancer; 2015 Dec; 13(6):548-54. PubMed ID: 26320661 [TBL] [Abstract][Full Text] [Related]
20. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Motzer RJ; Hutson TE; Tomczak P; Michaelson MD; Bukowski RM; Oudard S; Negrier S; Szczylik C; Pili R; Bjarnason GA; Garcia-del-Muro X; Sosman JA; Solska E; Wilding G; Thompson JA; Kim ST; Chen I; Huang X; Figlin RA J Clin Oncol; 2009 Aug; 27(22):3584-90. PubMed ID: 19487381 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]